Pharmacology of a new calcium antagonistic compound, isobutyl methyl 1,4-dihydro-2,6-dimethyl-4(2-nitrophenyl)-3,5-pyridinedicarboxylate (Nisoldipine, Bay k 5552).
D000818:Animals; D001777:Blood Coagulation / Q000187:drug effects; D002118:Calcium / Q000037:antagonists & inhibitors* / Q000494:pharmacology; D002415:Cats; D055598:Chemical Phenomena; D002621:Chemistry; D004231:Diuresis / Q000187:drug effects; D004285:Dogs; D005260:Female; D006168:Guinea Pigs; D006439:Hemodynamics / Q000187:drug effects; D006978:Hypertension, Renovascular / Q000188:drug therapy; D008297:Male; D009119:Muscle Contraction / Q000187:drug effects; D009130:Muscle, Smooth / Q000187:drug effects; D009131:Muscle, Smooth, Vascular / Q000187:drug effects; D009200:Myocardial Contraction / Q000187:drug effects; D009543:Nifedipine / Q000031:analogs & derivatives / Q000494:pharmacology*; D015737:Nisoldipine; D009638:Norepinephrine / Q000494:pharmacology; D011188:Potassium / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology*; D011817:Rabbits; D051381:Rats
D011725:Pyridines; D015737:Nisoldipine; D009543:Nifedipine; D011188:Potassium; D002118:Calcium; D009638:Norepinephrine